New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome

Pediatric Nephrology

Volumn 26, Issue 6, 2011, Pages 881-892

  Van Husen, Michael ^a   Kemper, Markus J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Focal segmental glomerulosclerosis; Immunosuppression; Minimal change glomerulonephritis; Nephrotic syndrome; Steroid resistant; Steroid sensitive

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LEVAMISOLE; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID; PLACEBO; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE;

B LYMPHOCYTE; BLEEDING; BONE MARROW SUPPRESSION; CYSTITIS; CYTOTOXICITY; FOCAL GLOMERULOSCLEROSIS; GONAD DYSFUNCTION; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LEUKOPENIA; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; STEROID RESISTANT NEPHROTIC SYNDROME; STEROID SENSITIVE NEPHROTIC SYNDROME; UNSPECIFIED SIDE EFFECT;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; LEVAMISOLE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; RECURRENCE;

EID: 79959970416     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-010-1717-5     Document Type: Review

References (96)

1. International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13:159-165
2. Murnaghan K, Vasmant D, Bensman A (1984) Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. Acta Paediatr Scand 73:733-739 (Pubitemid 15209673)
3. Hodson EM, Alexander SI (2008) Evaluation and management of steroid-sensitive nephrotic syndrome. Curr Opin Pediatr 20:145-150 (Pubitemid 351365703)
4. Hoyer PF, Brodehl J (2006) Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 17:1151-1157
5. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M (2003) A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 41:1155-1162 (Pubitemid 36637969)
6. MacHardy N, Miles PV, Massengill SF, Smoyer WE, Mahan JD, Greenbaum L, Massie S, Yao L, Nagaraj S, Lin JJ, Wigfall D, Trachtman H, Hu Y, Gipson DS (2009) Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 24:2193-2201
7. International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561-564
8. Ehrich JH, Brodehl J (1993) Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 152:357-361 (Pubitemid 23094416)
9. Rüth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147:202-207 (Pubitemid 41207834)
10. Niaudet P (2009) Long-term outcome of children with steroidsensitive idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 4:1547-1548
11. Davin JC, Merkus MP (2005) Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Pediatr Nephrol 20:10-14 (Pubitemid 40057846)
12. Kemper MJ, Altrogge H, Ludwig K, Timmermann K, Muller-Wiefel DE (2000) Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 14:772-775 (Pubitemid 30462165)
13. Vester U, Kranz B, Zimmermann S, Hoyer PF (2003) Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 18:661-664 (Pubitemid 36826850)
14. Sharda SV, Gulati S, Tripathi G, Jafar T, Kumar A, Sharma RK, Agrawal S (2008) Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome? Pediatr Nephrol 23:2001-2006
15. Kyrieleis HA, Levtchenko EN, Wetzels JF (2007) Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis 49:592-597 (Pubitemid 46654498)
16. Kyrieleis HA, Lowik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN (2009) Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 4:1593-1600
17. Prasad N, Gulati S, Sharma RK, Singh U, Ahmed M (2004) Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 19:494-498 (Pubitemid 38594286)
18. Kemper MJ, Kuwertz-Broeking E, Bulla M, Mueller-Wiefel DE, Neuhaus TJ (2004) Recurrence of severe steroid dependency in cyclosporin A-treated childhood idiopathic nephrotic syndrome. Nephrol Dial Transplant 19:1136-1141 (Pubitemid 38628132)
19. Hulton SA, Neuhaus TJ, Dillon MJ, Barratt TM (1994) Long-term cyclosporin A treatment of minimal-change nephrotic syndromeof childhood. Pediatr Nephrol 8:401-403 (Pubitemid 24228624)
20. Nozu K, Iijima K, Sakaeda T, Okumura K, Nakanishi K, Yoshikawa N, Honda M, Ikeda M, Matsuo M (2005) Cyclosporin A absorption profiles in children with nephrotic syndrome. Pediatr Nephrol 20:910-913 (Pubitemid 40909259)
21. Hodson EM, Willis NS, Craig JC (2008) Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev CD002290
22. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P, Altieri P, Bettinelli A, Maschio G, Cinotti GA, Fuiano G, Schena FP, Castellani A, Casa-Alberighi OD (1993) Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 8:1326-1332 (Pubitemid 24038066)
23. Sumegi V, Haszon I, Bereczki C, Papp F, Turi S (2008) Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 23:1085-1092
24. Kengne-Wafo S, Massella L, Diomedi-Camassei F, Gianviti A, Vivarelli M, Greco M, Stringini GR, Emma F (2009) Risk factors for cyclosporin A nephrotoxicity in children with steroiddependant nephrotic syndrome. Clin J Am Soc Nephrol 4:1409-1416
25. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y (2006) Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child 91:666-670 (Pubitemid 44197108)
26. Sinha MD, MacLeod R, Rigby E, Clark AG (2006) Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 21:1848-1854 (Pubitemid 43985712)
27. Dötsch J, Dittrich K, Plank C, Rascher W (2006) Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? Nephrol Dial Transplant 21:1761-1763 (Pubitemid 43985697)
28. Dittrich K, Knerr I, Rascher W, Dötsch J (2006) Transient insulindependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr Nephrol 21:958-961 (Pubitemid 43885094)
29. Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroiddependent nephrotic syndrome. Am J Kidney Dis 42:1114-1120 (Pubitemid 37486753)
30. Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19:101-104 (Pubitemid 38088259)
31. Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R (2006) Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 1:1173-1178
32. Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T (2009) Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol 72:268-273
33. Ulinski T, Dubourg L, Said MH, Parchoux B, Ranchin B, Cochat P (2005) Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 20:482-485 (Pubitemid 40392623)
34. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23:2013-2020
35. Mendizabal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J (2005) Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 20:914-919 (Pubitemid 40909260)
36. de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SP, de Andrade OV, Guidoni EB, Scheffer DK, Martini Filho D, Toporovski J, Benini V (2010) Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol 25:453-460
37. Kawasaki Y, Suzuki J, Takahashi A, Isome M, Nozawa R, Suzuki H (2005) Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol 20:96-98 (Pubitemid 40057863)
38. Durkan A, Hodson EM, Willis NS, Craig JC (2005) Noncorticosteroi treatment for nephrotic syndrome in children. Cochrane Database Syst Rev CD002290
39. Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE (2003 Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 60:242-247 (Pubitemid 37258847)
40. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269-1279
41. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321-1328
42. Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K (2010) Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25:461-468
43. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. doi:10.2215/CJN.03470410
44. Kemper MJ, Moeller C, Rink N, van Husen M, Mueller-Wiefel DE (2007) Treatment of refractory steroid sensitive nephrotic syndrome with rituximab. Pediatr Nephrol 22:1445
45. Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschenes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753-1755
46. Bitzan M, Anselmo M, Carpineta L (2009) Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol 44:922-934
47. Park SS, Hahn WH, Kim SD, Cho BS (2009) Remission of refractory minimal change nephrotic syndrome after basiliximab therapy. Pediatr Nephrol 24:1403-1407
48. Clark AG, Amlot P (1995) Anti-CD25 monoclonal antibody induces remission of steroid responsive nephrotic syndrome-a case report. Pediatr Nephrol 9:C86
49. Francois H, Daugas E, Bensman A, Ronco P (2007) Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 49:158-161 (Pubitemid 44932200)
50. Raveh D, Shemesh O, Ashkenazi YJ, Winkler R, Barak V (2004) Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome. Pediatr Nephrol 19:1281-1284 (Pubitemid 39462432)
51. Kausman JY, Yin L, Jones CL, Johnstone L, Powell HR (2005) Vincristine treatment in steroid-dependent nephrotic syndrome. Pediatr Nephrol 20:1416-1419 (Pubitemid 41403415)
52. Krishnan RG, Coulthard MG, Moghal NE (2006) Is there a role for vincristine in nephrotic syndrome? Pediatr Nephrol 21:597
53. Vehaskari VM (1999) Treatment practices of FSGS among North American pediatric nephrologists. Pediatr Nephrol 13:301-303 (Pubitemid 29243732)
54. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, Gibson K, Thomas DB (2006) Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 21:344-349 (Pubitemid 43280349)
55. Buescher AK, Kranz B, Buscher R, Hildebrandt F, Dworniczak B, Pennekamp P, Kuwertz-Broking E, Wingen AM, John U, Kemper M, Monnens L, Hoyer PF, Weber S, Konrad M (2010) Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. doi: 10.2215/CJN.01190210
56. Bhimma R, Adhikari M, Asharam K (2006) Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity. Pediatr Nephrol 21:1847-1853 (Pubitemid 44741162)
57. El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahmad N, Sobh M (2005) Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant 20:2433-2438 (Pubitemid 41548868)
58. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84-88
59. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J (2007) Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 22:2183-2193 (Pubitemid 47244695)
60. Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W (2008) Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 23:1483-1493
61. Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ (2010) Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol 25:899-903
62. Meyrier AY (2009) Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int 76:487-491
63. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931-938
64. Bensman A, Niaudet P (2010) Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 25:1197-1199
65. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A (1995) Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 5:1820-1825
66. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N (2007) Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 72:1429-1447 (Pubitemid 350197945)
67. Hamasaki Y, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Yata N, Kaneko T, Honda M (2009) Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 24:2177-2185
68. Segarra A, Vila J, Pou L, Majo J, Arbos A, Quiles T, Piera LL (2002) Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 17:655-662 (Pubitemid 34308823)
69. Duncan N, Dhaygude A, Owen J, Cairns TD, Griffith M, McLean AG, Palmer A, Taube D (2004) Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 19:3062-3067 (Pubitemid 40057629)
70. Westhoff TH, van der Giet M (2007) Tacrolimus in the treatment of idiopathic nephrotic syndrome. Expert Opin Investig Drugs 16:1099-1110 (Pubitemid 47074164)
71. Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J (2009) Tacrolimus therapy in adults with steroidand cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 54:51-58
72. Loeffler K, Gowrishankar M, Yiu V (2004) Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 19:281-287 (Pubitemid 38313011)
73. Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP (2008) Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 23:910-913 (Pubitemid 351767558)
74. Butani L, Ramsamooj R (2009) Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 24:1517-1523
75. Roberti I, Vyas S (2010) Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 25:1117-1124
76. Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A (2009) Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 53:760-769
77. Rennert WP, Kala UK, Jacobs D, Goetsch S, Verhaart S (1999) Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol 13:113-116 (Pubitemid 29206233)
78. Gulati S, Kher V (2000) Intravenous pulse cyclophosphamide-a new regime for steroid resistant focal segmental glomerulosclerosis. Indian Pediatr 37:141-148 (Pubitemid 30115040)
79. Al Salloum AA (2004) Pulse cyclophosphamide therapy for steroid-resistant focal segmental glomerulosclerosis in children. Ann Saudi Med 24:27-30 (Pubitemid 38195602)
80. Abeyagunawardena AS, Sebire NJ, Risdon RA, Dillon MJ, Rees L, Van't Hoff W, Kumarasiri PV, Trompeter RS (2007) Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 22:215-221 (Pubitemid 44964322)
81. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1996) Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 10:590-593
82. Cattran DC, Wang MM, Appel G, Matalon A, Briggs W (2004) Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 62:405-411 (Pubitemid 39654577)
83. El-Reshaid K, El-Reshaid W, Madda J (2005) Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis. Ren Fail 27:523-530 (Pubitemid 41216307)
84. Montane B, Abitbol C, Chandar J, Strauss J, Zilleruelo G (2003) Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 18:772-777 (Pubitemid 36949963)
85. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003) Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 18:833-837 (Pubitemid 36949975)
86. Gellermann J, Querfeld U (2009) Long-term outcome of idiopathic steroid resistant nephrotic syndrome-associated with focal segmental glomerulosclerosis: a single center study. Pediatr Nephrol 24:1807
87. Yabu JM, Ho B, Scandling JD, Vincenti F (2008) Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8:222-227
88. Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 356:2751-2752 (Pubitemid 47001064)
89. Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K (2008) Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23:481-485
90. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M (2008) Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151:288-292
91. De Smet E, Rioux JP, Ammann H, Deziel C, Querin S (2009) FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant 24:2938-2940
92. Cho ME, Hurley JK, Kopp JB (2007) Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 49:310-317 (Pubitemid 46178397)
93. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A (2006) A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 1:109-116
94. Tsagalis G, Psimenou E, Iliadis A, Nakopoulou L, Laggouranis A (2009) Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases. Am J Kidney Dis 54:340-344
95. Hocker B, Knuppel T, Waldherr R, Schaefer F, Weber S, Tonshoff B (2006) Recurrence of proteinuria 10 years post-transplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus. Pediatr Nephrol 21:1476-1479 (Pubitemid 44283483)
96. Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross ML (2008) Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 294: F748-F757